ArticleCancer medicine2021

Sequential CD19 and BCMA-specific CAR T-cell treatment elicits sustained remission of relapsed and/or refractory myeloma.

Lingzhi Yan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.